Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talzenna in BRCA-mutated advanced breast cancer
NCT02034916Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Dec 2013
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of talazoparib in breast cancer, sponsored by Pfizer. Started Dec 2013; status: terminated.
02
Drugs
talazoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02034916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034916.